

Program

Vaccines Summit-2024 | November 13-15 | Boston, MA

Keynote Presentations | Day-1 Nov-13 | GrandBall Room

EST (Eastern Time Zone)

Exhibitors



Registrations

Introduction: Opening Ceremony

Session Chair: David Weiner, Executive Vice President, The Wistar Institute, Director, Vaccine & Immunotherapy Center

Presentation Title: **Human *in vitro* Modeling and Systems Biology to Advance Precision Vaccines**

Ofer Levy, Staff Physician & Principal Investigator, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital Professor, Harvard Medical School

Presentation Title: TBD

Dan Barouch, Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center

Presentation Title: TBD

Walter Straus, Vice-President, Clinical Safety, Moderna

Presentation Title: TBD

Francesca Ceddia, Chief Medical Affairs Officer, Moderna

Presentation Title: TBD

David Weiner, Executive Vice President, The Wistar Institute, Director, Vaccine & Immunotherapy Center

Presentation Title: **Efficacy of dendritic-cell-based cancer vaccines enhanced by development in high omega-3 lipid environment**

Jay A. Berzofsky, National Cancer Institute, NIH

Presentation Title: TBD

Swati Gupta, VP, Emerging Infectious Diseases and Epidemiology, IAVI

Presentation Title: TBD

David Kaslow, Director, Office of Vaccines Research and Review, FDA/CBER

Presentation Title: TBD

William C. (Bill) Gruber, Former Senior Vice President, Vaccine Clinical Research and Development, WRDM, Pfizer Inc.

Presentation Title: TBD

Kate Broderick, Chief Innovation Officer, Maravai LifeSciences

Presentation Title: TBD

Hira Nakhasi, Division Director – DETTD, Center for Biologics Evaluation and Research

Presentation Title: TBD

Jerry Sadoff, Chief Medical Officer, Centivax

Presentation Title: TBD

Dave Liebowitz, Senior Vice President, Early-Stage Clinical Development, INOVIO

Presentation Title: TBD

Stephen L. Hoffman, Chief Executive and Scientific Officer, Sanaria Inc.

Reception @ Foyer

Poster Presentations

Use of the Abrysvo Vaccine in Pregnancy to Prevent RSV in Infants: A Review

Dhanvi Patel, Nova Southeastern University College of Osteopathic Medicine

Continued COVID-19 Vaccine Uncertainty in the United States in the Post-Pandemic Era

Hallie Cope, Ipsos

Utilizing neuromarketing testing to develop effective vaccine education

Allison Peltier, United Tribes Technical College

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines

Aurelie Wiedemann, INSERM/VRI

Conjugate vaccine | DAY-2 Nov-14 | GrandBall Room

Session Chair: Andrew Lees, Fina Biosolutions
Session Co-Chair: Robert van der Put, Intravacc.nl

Presentation Title: TBD
Andrew Lees, Fina Biosolutions

Turbo: an adjuvant platform for bacterial glycoconjugate vaccines
Kishore Alugupalli, TurboVax Inc

Presentation Title: TBD
Robert van der Put, Intravacc.nl

Design of a glycoconjugate vaccine against *Salmonella* Paratyphi A
Renzo Alfani, GSK Vaccines Institute for the Global Health

Study of CDAP chemistry as generic conjugation for development of glycoconjugate vaccines
Carlo Giannelli, GSK Vaccines Institute for the Global Health

Presentation Title: TBD
Gary R. Matyas, US Military HIV Research Program, Walter Reed Army Institute of Research

Presentation Title: TBD
Lars Bonfel, Vaxcyte

DAY-2 Nov-14

Session Chair:

New Vaccines Development

Presentation Title: **Innovative mRNA-Based HSV Vaccine: Achieving Complete Protection Against HSV-1 and HSV-2 Infections**
Rennhuan Xu, ARV Technologies, Inc.

Presentation Title: **Development of Next Generation Vaccine Platform**
Khursheed Anwer, IMUNON Corporation

Presentation Title: **Computational design of a potent pre-fusion protein as a human metapneumovirus vaccine**
Michael Kishko, Sanofi

Presentation Title: **The state of herpes simplex virus vaccine R&D**
Simon Delagrave, Herpes Cure Advocacy

Presentation Title:
Eleftheria Michalaki, Piezo Therapeutics

Presentation Title: **Recombinant fusion protein vaccine containing *Clostridioides difficile* FliC and FliD protects mice against *C. difficile* infection**
Xingmin Sun, University of South Florida

Presentation Title: **Prevention of tuberculosis in nonhuman primates by an attenuated *Mycobacterium tuberculosis* vaccine via induction of adaptive T cell responses**
Deepak Kaushal, Texas Biomedical Research Institute

Presentation Title:
Stephen J. Dollery, Biological Mimetics, Inc

Presentation Title: TBD
Ricardo da Silva Antunes, Instructor at La Jolla Institute for Immunology

| **DAY-3 Nov-15** | **GrandBall Room**

Cancer Vaccines

Presentation Title: **A Platform for Personal Cancer Vaccine Immunotherapy Targeting Tumor-Initiating Cells**
Robert O. Dillman, AIVITA Biomedical, Inc.

Presentation Title: **Novel biologics platform for antigen-specific T cell modulation**
Steven Almo, Albert Einstein College of Medicine

Presentation Title: **SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity Through B Cell Antigen Presentation**
Duxin Sun, College of Pharmacy, University of Michigan

Presentation Title: **Oncolytic Viral Cancer Vaccines: Overcoming Hurdles in the Realm of mRNA Tumor Vaccines**
William Jia, ViroGen Biotech

Presentation Title: **Targeting Langerhans cells using trimeric Env of HIV triggers a swift and robust production of Env-specific IgG antibodies and neutralizing antibodies through a Tfh/germinal center (GC) reaction**
Sylvain Cardinaud, Vaccine Research Institute / Inserm

Presentation Title: **Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases**
Aurelie Wiedemann, Vaccine Research Institute / Inserm

SPEAKING SLOTS ARE AVAILABLE

Note: This is a tentative program and subject to change